US BANCORP \DE\ - AIMMUNE THERAPEUTICS INC ownership

AIMMUNE THERAPEUTICS INC's ticker is AIMT and the CUSIP is 00900T107. A total of 152 filers reported holding AIMMUNE THERAPEUTICS INC in Q3 2019. The put-call ratio across all filers is 1.27 and the average weighting 0.5%.

Quarter-by-quarter ownership
US BANCORP \DE\ ownership history of AIMMUNE THERAPEUTICS INC
ValueSharesWeighting
Q2 2020$104,000
+15.6%
6,214
-0.1%
0.00%
Q1 2020$90,000
-46.7%
6,222
+22.9%
0.00%
Q4 2019$169,000
+131.5%
5,064
+44.3%
0.00%
Q3 2019$73,000
+87.2%
3,510
+117.2%
0.00%
Q4 2018$39,000
-11.4%
1,6160.0%0.00%
Q3 2018$44,000
+2.3%
1,6160.0%0.00%
Q2 2018$43,000
-15.7%
1,6160.0%0.00%
Q1 2018$51,000
-16.4%
1,6160.0%0.00%
Q4 2017$61,0001,6160.00%
Other shareholders
AIMMUNE THERAPEUTICS INC shareholders Q3 2019
NameSharesValueWeighting ↓
Aisling Capital LLC 1,240,000$25,966,00057.34%
Foresite Capital Management II, LLC 2,605,499$54,559,00011.53%
Foresite Capital Management III, LLC 611,893$12,813,0004.89%
Palo Alto Investors LP 3,471,740$72,698,0004.84%
SANDERS MORRIS HARRIS LLC 486,906$10,196,0002.47%
Eventide Asset Management 3,084,000$64,579,0002.13%
Sofinnova Investments, Inc. 346,770$7,261,0000.66%
EMERALD ADVISERS, LLC 610,511$12,784,0000.60%
RICE HALL JAMES & ASSOCIATES, LLC 752,358$15,754,0000.56%
EMERALD MUTUAL FUND ADVISERS TRUST 587,464$12,301,0000.54%
View complete list of AIMMUNE THERAPEUTICS INC shareholders